TokenPost·

MapLight Therapeutics Posts $0.97 Q3 GAAP Loss Per Share, Beats Estimates

Your call?

MapLight Therapeutics, Inc. had $463.4 million in cash, cash equivalents and investments as of Sept. 30.

Share

More news